683 Capital Management LLC Purchases 685,000 Shares of Amicus Therapeutics, Inc. $FOLD

683 Capital Management LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 249.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 960,000 shares of the biopharmaceutical company’s stock after buying an additional 685,000 shares during the period. 683 Capital Management LLC’s holdings in Amicus Therapeutics were worth $5,501,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of FOLD. Invesco Ltd. grew its position in shares of Amicus Therapeutics by 4.1% during the first quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock worth $21,717,000 after purchasing an additional 105,856 shares in the last quarter. Norges Bank purchased a new position in Amicus Therapeutics in the 2nd quarter worth approximately $18,540,000. Jump Financial LLC boosted its stake in Amicus Therapeutics by 246.3% in the 2nd quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company’s stock worth $8,060,000 after purchasing an additional 1,000,395 shares during the period. Capital Fund Management S.A. grew its holdings in Amicus Therapeutics by 408.8% during the 1st quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock valued at $2,550,000 after buying an additional 251,134 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Amicus Therapeutics by 26.4% during the 1st quarter. Deutsche Bank AG now owns 1,038,990 shares of the biopharmaceutical company’s stock valued at $8,478,000 after buying an additional 216,882 shares in the last quarter.

Analyst Ratings Changes

FOLD has been the topic of several research analyst reports. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday. JPMorgan Chase & Co. boosted their price target on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. The Goldman Sachs Group increased their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Finally, Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Jeff Castelli sold 76,158 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the sale, the insider directly owned 439,318 shares of the company’s stock, valued at $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bradley L. Campbell sold 14,587 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $10.01, for a total value of $146,015.87. Following the sale, the chief executive officer owned 1,137,282 shares in the company, valued at approximately $11,384,192.82. This trade represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 216,239 shares of company stock worth $2,165,304. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $10.55 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $11.00. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The firm’s fifty day moving average is $9.14 and its 200 day moving average is $7.64. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -263.68 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. During the same period last year, the company posted $0.10 EPS. The business’s revenue was up 19.5% on a year-over-year basis. Sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.